Research programme: BBB-ve 2nd Gen METTL3 inhibitors - Storm Therapeutics [78656]
Latest Information Update: 08 Jul 2024
Price :
$50 *
At a glance
- Originator Storm Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action METTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jun 2024 Preclinical trials in Cancer in United Kingdom (Storm Therapeutics pipeline, June 2024)